The National Pharmaceutical Pricing Authority (NPPA), introduced a 30% cap on trade margins for 137 specified non-scheduled anti-cancer medicines to reduce excessive mark-ups across the pharmaceutical supply chain and improve affordability of cancer treatment. The initiative applies to both branded and generic versions of the covered formulations listed in Table B of the relevant NPPA notification.
Under the revised pricing mechanism, the permissible Maximum Retail Price (MRP) will be determined based on the manufacturer-to-stockist or manufacturer-to-distributor price, excluding GST, and the prescribed pricing formula. The 30% cap applies to the trade margin and does not mean that every covered medicine will become 30% cheaper. Manufacturers must implement revised prices, while hospitals, medical institutions, pharmacies, retailers and dealers must comply with applicable pricing and price-display requirements. Hospitals and medical institutions must also prominently display revised prices on their websites. Existing Patient Assistance Programmes are not expected to be affected.
The revised pricing mechanism shall come into effect from November 9, 2026, and remain in force until further orders. Patients can verify prices through the NPPA website or Pharma Sahi Daam app/portal. Complaints regarding overcharging may be submitted to NPPA through the Pharma Sahi Daam platform, email at [email protected] or helpline 1800-11-1255, with supporting purchase invoices and medicine details.
